Keywords: GlaxoSmithKline, ChemoCentryx, Milestone, Rheumatoid arthritis, CCX354, Option

Milestone for ChemoCentryx as GSK exercises license option

Article | 06 January 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) has exercised its option to obtain an exclusive license for further development and worldwide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in